Anavex withdraws EU bid for Alzheimer's drug; stock tanks 20%

Anavex Life Sciences stock plummeted over 20% pre-market after withdrawing its EU marketing application for Alzheimer's drug blarcamesine. The decision followed feedback from the European Medicines Agency. This setback comes just two days after the company reported positive clinical data suggesting the treatment could slow brain shrinkage in patients.